Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil

Brazilian Journal of Infectious Diseases

Volumn 12, Issue 5, 2008, Pages 368-373

  Costa, Anna Maria N ^a   Italien, Gilbert L ^b   Nita, Marcelo Eidi ^a   Araujo, Evaldo Stanislau A ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b Global Epidemiology and Outcome Research   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic hepatitis B; Cost; Treatment

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE;

ARTICLE; BRAZIL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MORTALITY; PUBLIC HEALTH PROBLEM; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; VIRUS LOAD; VIRUS REPLICATION; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG EFFECT; ECONOMICS; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 65449161437     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702008000500005     Document Type: Article

References (21)

1. Ministério da Saúde - Programa Nacional de Hepatites Virais. Avaliação da Assistência às Hepatites Virais no Brasil. Brasília;2002:1-61.
2. Ministério da Saúde - Programa Nacional para a Prevenção e o Controle das Hepatites Virais. Disponível em: http://www.saude.gov.br/sps/areastecnicas/ hepatite.htm. 2007.
3. Lok A.S.F., McMahon B.J. Chronic hepatitis B. Hepatology 2001; 34:1225-41.
4. Keeffe E.B., Dieterich D.T., Han S.H., et al A treatment algorithm for management of chronic hepatitis b vírus infection in the United States: na update. Clin Gastroenterol Hepatol 2006;4:936-62.
5. Hoofnagle J.H. Hepatitis B - Preventable and now treatable. N Engl J Med 2006;354:1074-6.
6. Dienstag J.L., Lee-Jen Wei, Dong Xu, Bruce Kreter. Cross-study analysis of relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Invest 2007; 27:35-49.
7. Chang T.T., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
8. Lai C.L., et al. Entecavir versus lamivudine for patients with HBenegative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
9. Chen C.J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73;
10. Iloeje U.H., et al. Predicting cirrhosis risk base don the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
11. Chang T.T., Gish R.G., Man R., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
12. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with AgHBe-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
13. Castelo A., Pessoa M.G., Barreto T.C.B.B. Estimativas de custo da hepatite B crônica no sistema único de saúde brasileiro em 2005. Rev Assoc Med Bras 2007;53:486-91.
14. Instituto Brasileiro de Geografia e Estatística (IBGE). Disponível em: www.ibge.gov.br. 2008.
15. Durand-Zaleski I., Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making 1994;14:98-03.
16. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
17. Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
18. Levy A.R., Kowdley K.V., Iloeje U., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health 2007 (December).
19. Veenstra D.L., Sullivan S.D., Clarke L., et al. Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25:963-77.
20. Kanwal F., Farid M., Martin P., et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
21. Yuan Y., Iloeje U.H., Hay J., Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAgpositive chronic hepatitis B patients. J Manag Care Pharm 2008;14:21-33.